TY - JOUR
T1 - Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK)
T2 - A French nationwide cohort retrospective study
AU - Duruisseaux, Michaël
AU - Besse, Benjamin
AU - Cadranel, Jacques
AU - Pérol, Maurice
AU - Mennecier, Bertrand
AU - Bigay-Game, Laurence
AU - Descourt, Renaud
AU - Dansin, Eric
AU - Audigier-Valette, Clarisse
AU - Moreau, Lionel
AU - Hureaux, José
AU - Veillon, Remi
AU - Otto, Josiane
AU - Madroszyk-Flandin, Anne
AU - Cortot, Alexis
AU - Guichard, François
AU - Boudou-Rouquette, Pascaline
AU - Langlais, Alexandra
AU - Missy, Pascale
AU - Morin, Franck
AU - Moro-Sibilot, Denis
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in a large population of unselected patients with ALK-positive non-smallcell lung cancer (NSCLC) is not documented. We sought to assess OS with crizotinib in unselected ALK-positive NSCLC patients and whether post-progression systemic treatments affect survival outcomes. ALK-positive NSCLC patients receiving crizotinib in French expanded access programs or as approved drug were enrolled. We collected clinical and survival data, RECIST-defined progressive disease (PD) and post-PD systemic treatment efficacy. We performed multivariable analysis of OS from crizotinib initiation and PD under crizotinib. At time of analysis, 209 (65.7%) of the 318 included patients had died. Median OS with crizotinib was 16.6 months. The line of crizotinib therapy did not impact survival outcomes. Of the 263 patients with PD, 105 received best supportive care, 74 subsequent drugs other than next-generation ALKi and 84 next-generation ALKi. Nextgeneration ALKi treatment correlated with better survival outcomes in multivariate analysis. These patients had a median post-PD survival of 25.0 months and median OS from metastatic disease diagnosis of 89.6 months. Unselected ALK-positive NSCLC patients achieve good survival outcomes with crizotinib therapy. Next-generation ALKi may provide survival improvement after PD under crizotinib.
AB - Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in a large population of unselected patients with ALK-positive non-smallcell lung cancer (NSCLC) is not documented. We sought to assess OS with crizotinib in unselected ALK-positive NSCLC patients and whether post-progression systemic treatments affect survival outcomes. ALK-positive NSCLC patients receiving crizotinib in French expanded access programs or as approved drug were enrolled. We collected clinical and survival data, RECIST-defined progressive disease (PD) and post-PD systemic treatment efficacy. We performed multivariable analysis of OS from crizotinib initiation and PD under crizotinib. At time of analysis, 209 (65.7%) of the 318 included patients had died. Median OS with crizotinib was 16.6 months. The line of crizotinib therapy did not impact survival outcomes. Of the 263 patients with PD, 105 received best supportive care, 74 subsequent drugs other than next-generation ALKi and 84 next-generation ALKi. Nextgeneration ALKi treatment correlated with better survival outcomes in multivariate analysis. These patients had a median post-PD survival of 25.0 months and median OS from metastatic disease diagnosis of 89.6 months. Unselected ALK-positive NSCLC patients achieve good survival outcomes with crizotinib therapy. Next-generation ALKi may provide survival improvement after PD under crizotinib.
KW - ALK
KW - Alectinib
KW - Ceritinib
KW - Crizotinib
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85016401342&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.15746
DO - 10.18632/oncotarget.15746
M3 - Article
C2 - 28423535
AN - SCOPUS:85016401342
SN - 1949-2553
VL - 8
SP - 21903
EP - 21917
JO - Oncotarget
JF - Oncotarget
IS - 13
ER -